Multiple indications for everolimus after liver transplantation in current clinical practice

Table 2 Causes of conversion and other comorbidities at the time of conversion to everolimus in 74 liver transplant patients n (%)

Cause of conversion
Refractory rejection	23 (31.1)	Resolution	17 (73.9)
Extended HCC in explanted liver	14 (19)	Prevention of recurrence	7 (50)
HCC recurrence during follow-up	6 (8.1)	Stabilization	0 (0)
De novo tumour	13 (17.6)	Prevention of recurrence	8 (61.5)
CNI-related neurotoxicity	8 (10.8)	Resolution or Stabilization	8 (100)
Renal dysfunction	6 (8.1)	Resolution or Amelioration	3 (50)
Other causes	4 (5.4)	Resolution	2 (50)
Comorbidity at time of conversion
Chronic renal insufficiency	22 (29.8)	Resolution or Amelioration	15 (68.2)
Diabetes mellitus	21 (28.4)	Resolution or Amelioration	8 (38)
Arterial hypertension	25 (33.8)	Resolution or Amelioration	3 (12)
Dyslipidemia	30 (40.5)	Resolution or Amelioration	2 (6.7)

Outcome to everolimus shown as resolution, stabilization or amelioration of the cause or comorbidity. In 45 of 74 patients (60.8%), the cause was resolved, stabilized or ameliorated. HCC: Hepatocellular carcinoma; CNI: Calcineurin inhibitors. Other causes include: 1 chronic biliary cirrhosis recurrence plus chronic rejection, 1 sinusoidal hepatic fibrosis, 1 graft-versus-host disease, 1 chronic cholostatic liver dysfunction in the postoperative period.